Page 1

Glenmark Pharmaceuticals Limited Statement of unaudited financial results for the quarter and half year ended 30 September , 2021 ( All amounts in million of Indian Rupees , unless otherwise stated ) 1 Revenue from operations ( a ) Net sales Particulars ( b ) Other operating income Total revenue from operations ] [ Other income 1 [ 1 Quarter ended 30/09/2021 ( Unaudited ) Quarter ended 30/06/2021 ( Unaudited ) Quarter ended 30/09/2020 ( Unaudited ) в Glenmark A new way for a new world Standalone Half year ended 30/09/2021 ( Unaudited ) Half year ended 30/09/2020 ( Unaudited ) Year ended 31/03/2031 ( Audited ) 21,598.94 209.72 21,808.66 21,292.40 128.77 21,421.17 20,254.92 366.73 20,621.65 42,891.34 338.49 43,229,83 36,779.37 671.50 37,450.87 74,509.11 1,170.22 75,679.33 806.96 1,382.08 634.04 2,189.04 1,982.53 3,962.37 Total income ( I + II ) 22,615.62 22,803.25 21,255.69 45,418,87 39,433.40 79,641.70 IV Expenses ( a ) Cost of materials consumed 8,144.13 8,459.53 7,503.36 16,603.66 13,420,77 26,782,60 ( b ) Purchases of stock - in - trade 1,180.91 1,401.60 658.51 2,582.51 1,421,24 3,159,55 ( c ) Changes in inventories of finished goods , work - in- progress and stock - in - trade ( 44.53 ) 41.27 41.63 ( 3.26 ) ( 115.61 ) 52.40 ( d ) Employee benefits expense 3,491.84 2,641.22 3,375.76 6,133,06 5,748.12 11,073.96 ( e ) Finance costs 532.45 590.15 604.12 1,122.60 1,203.50 2,658.98 ( 0 ) Depreciation , amortisation and impairment expense 396.83 374.42 367.94 771.25 726.03 1,508.15 ( g ) Other expenses 4,441.25 3,311.07 4,088.84 7,752,32 6,935.36 15,707.41 Total expenses ( IV ) 18,142.88 16,819.26 16,640,16 34,962.14 29,339 41 60,943.05 > Profit / ( loss ) before exceptional items and tax ( III - IV ) 4,472,74 5,983.99 4,615.53 10,456.73 10,093.99 18,698,65 VI Exceptional items ( gain ) ( Refer note 5 ) = VII Profit / ( loss ) before tax ( V - VI ) VIII Tax expense Current tax Deferred tax ( 4,303.33 ) ( 4,303.33 ) ( 279.90 ) ( 738.92 ) 8,776.07 5,983.99 4,615.53 14,760.06 10,373.89 19,437,57 1,250.76 ( 17.27 ) 1,050.89 38.95 802.53 ( 215.76 ) 2,301,65 21,68 1,814.86 ( 94.48 ) 3,436.18 ( 493.08 ) 1X Profit / ( loss ) for the period ( VII - VIII ) 7,542 58 4,894.15 4,028.76 12,436,73 8,653.51 16,494.47 Profit / ( loss ) for the period attributable to : - Non - controlling interests - Owners of the Company 7,542.58 4,894.15 4,028.76 12,436.73 8,653.51 16,494.47 Other comprehensive income A ( i ) Items that will not be reclassified to profit or loss . ( i ) Income tax relating to items that will not be reclassified to profit or loss B ( i ) Items that will be reclassified to profit or loss ( 21.48 ) 25.65 5.44 4,17 10.95 32.33 8.23 ( 8.96 ) ( 1.90 ) ( 0.73 ) ( 3.83 ) ( 7.49 ) ( ii ) Income tax relating to items that will be reclassified to profit or loss XI Total comprehensive income 7,529.33 4,910 84 4,032,30 12,440,17 8,660.63 16,519.31 XII Total comprehensive income attributable to : - Non - controlling interests - Owners of the Company 7,529.33 4,910.84 4,032,30 12,440.17 8,660.63 16,519,31 XIII Paid up Equity Share Capital , Equity Shares of Rs . 1 / - each 282.17 282.17 282.17 282,17 282.17 282.17 XIV Other equity 1,47,812,89 XV Earning per share ( EPS ) ( of Re 1 / - each ) ( not annualised ) * Basic EPS ( in Rupees ) Diluted EPS ( in Rupees ) 26.73 26.73 17.34 17.34 14.28 14.28 44.08 44.08 30.67 58.46 30.67 58.46 except for the year ended 31 March SURANA & ASSOCIAT Glenmark Pharmaceuticals Ltd. Glenmark House , B D Sawant Marg , Andheri ( E ) , Mumbai - 400 099 , India SURES Chartered Accountants MUMBAI ES LLP T : 91 22 4018 9999 F : 91 22 4018 9986 CIN No : L24299MH1977PLC019982 W : www.glenmarkpharma.com Registered office : B / 2 , Mahalaxmi Chambers , 22 Bhulabhai Desai Road , Mumbai 400 026 E : complianceofficer@glenmarkpharma.com GLENN PHAR MUMBAI CEUTICALS LTD .